{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "SARS-CoV-2 attachment and entry",
      "antiviral therapy",
      "cholesterol-rich lipid rafts",
      "immune response"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34975904",
  "DateCompleted": {
    "Year": "2022",
    "Month": "01",
    "Day": "19"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "02"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "12",
        "Day": "16"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "796855",
      "10.3389/fimmu.2021.796855"
    ],
    "Journal": {
      "ISSN": "1664-3224",
      "JournalIssue": {
        "Volume": "12",
        "PubDate": {
          "Year": "2021"
        }
      },
      "Title": "Frontiers in immunology",
      "ISOAbbreviation": "Front Immunol"
    },
    "ArticleTitle": "Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry.",
    "Pagination": {
      "StartPage": "796855",
      "MedlinePgn": "796855"
    },
    "Abstract": {
      "AbstractText": [
        "Since its appearance, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), the causal agent of Coronavirus Disease 2019 (COVID-19), represents a global problem for human health that involves the host lipid homeostasis. Regarding, lipid rafts are functional membrane microdomains with highly and tightly packed lipid molecules. These regions enriched in sphingolipids and cholesterol recruit and concentrate several receptors and molecules involved in pathogen recognition and cellular signaling. Cholesterol-rich lipid rafts have multiple functions for viral replication; however, their role in SARS-CoV-2 infection remains unclear. In this review, we discussed the novel evidence on the cholesterol-rich lipid rafts as a platform for SARS-CoV-2 entry, where receptors such as the angiotensin-converting enzyme-2 (ACE-2), heparan sulfate proteoglycans (HSPGs), human Toll-like receptors (TLRs), transmembrane serine proteases (TMPRSS), CD-147 and HDL-scavenger receptor B type 1 (SR-B1) are recruited for their interaction with the viral spike protein. FDA-approved drugs such as statins, metformin, hydroxychloroquine, and cyclodextrins (methyl-\u03b2-cyclodextrin) can disrupt cholesterol-rich lipid rafts to regulate key molecules in the immune signaling pathways triggered by SARS-CoV-2 infection. Taken together, better knowledge on cholesterol-rich lipid rafts in the SARS-CoV-2-host interactions will provide valuable insights into pathogenesis and the identification of novel therapeutic targets."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 Palacios-R\u00e1palo, De Jes\u00fas-Gonz\u00e1lez, Cordero-Rivera, Farfan-Morales, Osuna-Ramos, Mart\u00ednez-Mier, Quisti\u00e1n-Galv\u00e1n, Mu\u00f1oz-P\u00e9rez, Bernal-Dolores, del \u00c1ngel and Reyes-Ruiz."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico."
          }
        ],
        "LastName": "Palacios-R\u00e1palo",
        "ForeName": "Selvin No\u00e9",
        "Initials": "SN"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico."
          }
        ],
        "LastName": "De Jes\u00fas-Gonz\u00e1lez",
        "ForeName": "Luis Adri\u00e1n",
        "Initials": "LA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico."
          }
        ],
        "LastName": "Cordero-Rivera",
        "ForeName": "Carlos Daniel",
        "Initials": "CD"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico."
          }
        ],
        "LastName": "Farfan-Morales",
        "ForeName": "Carlos Noe",
        "Initials": "CN"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico."
          }
        ],
        "LastName": "Osuna-Ramos",
        "ForeName": "Juan Fidel",
        "Initials": "JF"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Unidad M\u00e9dica de Alta Especialidad, Hospital de Especialidades No. 14, Centro M\u00e9dico Nacional \"Adolfo Ruiz Cortines\", Instituto Mexicano del Seguro Social (IMSS) Veracruz Norte, Veracruz, Mexico."
          }
        ],
        "LastName": "Mart\u00ednez-Mier",
        "ForeName": "Gustavo",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Unidad M\u00e9dica de Alta Especialidad, Hospital de Especialidades No. 14, Centro M\u00e9dico Nacional \"Adolfo Ruiz Cortines\", Instituto Mexicano del Seguro Social (IMSS) Veracruz Norte, Veracruz, Mexico."
          }
        ],
        "LastName": "Quisti\u00e1n-Galv\u00e1n",
        "ForeName": "Judith",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Unidad M\u00e9dica de Alta Especialidad, Hospital de Especialidades No. 14, Centro M\u00e9dico Nacional \"Adolfo Ruiz Cortines\", Instituto Mexicano del Seguro Social (IMSS) Veracruz Norte, Veracruz, Mexico."
          }
        ],
        "LastName": "Mu\u00f1oz-P\u00e9rez",
        "ForeName": "Armando",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Unidad M\u00e9dica de Alta Especialidad, Hospital de Especialidades No. 14, Centro M\u00e9dico Nacional \"Adolfo Ruiz Cortines\", Instituto Mexicano del Seguro Social (IMSS) Veracruz Norte, Veracruz, Mexico."
          }
        ],
        "LastName": "Bernal-Dolores",
        "ForeName": "V\u00edctor",
        "Initials": "V"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectomics and Molecular Pathogenesis, Center for Research and Advanced Studies (CINVESTAV-IPN), Mexico City, Mexico."
          }
        ],
        "LastName": "Del \u00c1ngel",
        "ForeName": "Rosa Mar\u00eda",
        "Initials": "RM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Unidad M\u00e9dica de Alta Especialidad, Hospital de Especialidades No. 14, Centro M\u00e9dico Nacional \"Adolfo Ruiz Cortines\", Instituto Mexicano del Seguro Social (IMSS) Veracruz Norte, Veracruz, Mexico."
          }
        ],
        "LastName": "Reyes-Ruiz",
        "ForeName": "Jos\u00e9 Manuel",
        "Initials": "JM"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Front Immunol",
    "NlmUniqueID": "101560960",
    "ISSNLinking": "1664-3224"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Spike Glycoprotein, Coronavirus"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "beta-Cyclodextrins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "methyl-beta-cyclodextrin"
    },
    {
      "RegistryNumber": "4QWG6N8QKH",
      "NameOfSubstance": "Hydroxychloroquine"
    },
    {
      "RegistryNumber": "97C5T2UQ7J",
      "NameOfSubstance": "Cholesterol"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "metabolism",
        "prevention & control",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Cholesterol"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Hydroxychloroquine"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Membrane Microdomains"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Protein Binding"
    },
    {
      "QualifierName": [
        "metabolism",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Spike Glycoprotein, Coronavirus"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Virus Internalization"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "beta-Cyclodextrins"
    }
  ],
  "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."
}